AR and prostate carcinoma: Emerging strategies to therapeutically target GATA2 in prostate cancer include the GATA2 small molecule inhibitor K7174 which suppresses the expression of AR, AR splice variants, and AR target genes via a posttranscriptional mechanism of inhibition (48).